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Introduction
Focal segmental glomerulosclerosis (FSGS) is a frequent
cause of end-stage renal disease (ESRD) in children and
adults. As with other progressive renal diseases, kidney
transplantation should represent the treatment of choice
also for patients with FSGS. However, some physicians
are reluctant to accept patients with FSGS for kidney
transplantation, being concerned that recurrence of the
original disease on the transplanted kidney, perhaps
caused by circulating factors [1,2], can lead to an early
graft failure. Actually, the available studies reported that
14–57% of transplanted children had a recurrence of
FSGS [3–10] and about half of them eventually lost their
allograft [11]. The North American Pediatric Renal Trans-
plant Cooperative Study [12] reported a mean graft sur-
vival of <6 years in adolescents with FSGS transplanted
either from living related or deceased donors. The United
Network for Organ Sharing (UNOS) database [13] also
showed a reduced graft survival rate for Caucasian chil-
dren with FSGS when compared with other primary renal
diseases.
Only a few articles have reported the outcome of renal
transplantation in adults with FSGS, [14–16]. The
reported risk of recurrence ranged from 34% to 48%, and
again recurrence was associated with a poor graft survival.
In 1990, we reported the outcome of 24 adults with
FSGS who received 25 renal transplants in our Unit from
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Summary
Little information is available about the long-term results of kidney transplan-
tation in adults with focal segmental glomerulosclerosis (FSGS). The outcomes
of 52 renal transplants performed between 1988 and 2008 in 47 adults with
FSGS were compared with those of 104 matched controls (median follow-up
93.4 vs. 109.4 months respectively). At 15 years, patient survival was 100% and
graft survival 56% in FSGS patients vs. 88.3% and 64% respectively in controls
(P = NS). FSGS recurred in 12 out of 52 grafts (23%) and led to graft failure
in seven within 10 months (median). In the other five cases, proteinuria remit-
ted and grafts are functioning 106 months (median) after transplantation. A
second recurrence developed in five out of eight re-transplanted patients
(62.5%) who lost their first graft because of recurrence; only one graft was lost.
Patients with recurrence were more frequently male subjects (83% vs. 40%,
P = 0.02), younger at diagnosis of FSGS (16.3 ± 6.8 vs. 24.1 ± 11.5 years,
P = 0.03) and of younger age at transplantation (28.4 ± 7.8 vs. 35.8 ±
12.2 years, P = 0.05). Treatment with plasmapheresis plus ACE inhibitors
achieved either complete or partial remission in 80% of the cases. Long-term
patient and renal allograft survivals of adults with FSGS were comparable to
those of controls. Recurrence was more frequent in young patients and in
patients who lost a previous graft from recurrence. Graft loss resulting from a
second recurrence is lower than expected.
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June 1969 to June 1988 [14]. In this article, we have
re-evaluated the experience in our Unit of patients with
FSGS transplanted during the period between July 1988
and July 2008. The aims of this single-center retrospective
analysis were (i) to evaluate the long-term patient and
renal allograft survival of FSGS with those of well-matched
controls, (ii) to compare the long-term renal and patient
survival and the complications in these two groups, and
(iii) to evaluate if the rate, the outcome and the predictors
of recurrence in renal transplant recipients with FSGS
have changed during the last 20 years in comparison to
that reported in the previous 20 years in our Unit.
Subjects and methods
Patients
Of 1300 renal transplants (1034 from deceased and 266
from living donors) performed in our Unit between the
period July 1988 and July 2008, 52 (4%) were performed
on 47 adults (>18 years) with ESRD resulting from
biopsy-proven primary FSGS (five patients received two
renal transplants). Five patients who lost the first graft
because of recurrence before this study (included in the
article of Banfi et al. [14]), were re-transplanted after
1988. Nine patients received a graft from a living donor.
Thirteen patients with secondary forms of FSGS were
excluded from the study.
Patients who received a renal transplant in the same
period (±3 months before or after transplantation of
patients with FSGS), matched for age (±5 years), gender
and source of the donor (deceased/living) were chosen as
controls. Of 104 controls, 13 were carriers of autosomal
dominant polycystic kidney disease, 22 had congenital
urinary tract abnormalities, 44 had glomerular diseases
(IgA glomerulonephritis 13 patients, membranoprolifera-
tive glomerulonephritis 9, lupus nephritis 4, Henoch-
Schonlein purpura 4, crescentic glomerulonephritis 1, AA
amyloidosis 1, AL amyloidosis 1, chronic nonbiopsied
glomerulonephritis 11); six patients had hypertensive
nephrosclerosis, one had chronic pyelonephritis, one post-
partum bilateral cortical necrosis, one hemolytic uremic
syndrome, three had nephronophthisis, four had Alport’s
syndrome, and eight patients had renal failure of
unknown origin. All FSGS patients and controls were
Caucasian.
Zero allograft biopsies were not performed in FSGS
patients and in controls.
Definitions
Recurrence was suspected by the discovery of proteinuria
and confirmed by graft biopsy. Recurrence was defined by
the presence of segmental or focal glomerulosclerosis on
light microscopy or diffuse effacement of epithelial foot
processes on electron microscopy.
Acute rejection was diagnosed on the basis of a double-
checked increase of 20% or more in plasma creatinine
over the baseline which could not be explained by other
causes. In patients who underwent graft biopsy, the rejec-
tion and the chronic histologic lesions were scored retro-
spectively according to the recently revised Banff
classification [17]:
Unspecific sclerosing lesions were defined as: interstitial
fibrosis with tubular atrophy and glomerular and arterio-
lar sclerosis, without evidence of any specific etiology.
Chronic rejection was defined by the presence of chronic
allograft arteriopathy and/or chronic transplant glomerul-
opathy.
Severe infections: those requiring hospitalization
Arterial hypertension: supine diastolic blood pressure
>90 mmHg and/or systolic blood pressure >140 mmHg
in three consecutive measurements.
Plasmapheresis (PLX) was performed with a Bellco
Lynda machine (Mirandola, Italy) with one plasma vol-
ume exchange per session and 5% albumin replacement:
three sessions per week during the first 3 weeks followed
by two sessions per week during 3 weeks and then tai-
lored to the response.
Immunosuppression
Fifteen grafts (29%) in the FSGS group and 25 (24%) in
the control group were given prednisone and cyclosporine
(CsA), two patients (2.8%) in FSGS group and seven in
the control group (6.7%) received CsA alone. Eighteen
FSGS patients (35%) and 40 (38%) controls received a
triple therapy with prednisone, CsA and azathioprine or
mycophenolate mofetil (MMF). Thirteen FSGS patients
(25%) and 29 controls (28%) received prednisone tacroli-
mus and MMF. Four FSGS patients (7.6%) and two con-
trols (1.9%) received sirolimus plus CsA and prednisone.
One patient in the control group received prednisone,
sirolimus and MMF.
Acute cellular rejections were treated with intravenous
methylprednisolone pulse (MPP) therapy, and acute vas-
cular rejections with anti-thymocyte globulins.
Treatment of recurrences of FSGS
In patients at first renal transplant, the treatment for
recurrence consisted of ACE inhibitors (enalapril), with
the exception of one patient intolerant to these drugs who
received MPP therapy. ACE-inhibitor was started at 10 mg
day and progressively increased to 20 mg twice a day if tol-
erated. In nonresponsive patients, PLX was associated. In
patients who lost their first renal transplant because of
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recurrence, the treatment of the second recurrence con-
sisted of ACE inhibitors associated with PLX, with the
exception of one patient who developed severe allergic
reaction to PLX and who was treated with ACE inhibitors
alone. This approach was the result of the experience
acquired during the management of these patients.
Statistical analysis
The statistical package S-Plus was used to analyse sample
data. Means ± SDs and median and interquartile (IQ)
range (25–75 percentile) were used for descriptive anal-
ysis. t-Test and nonparametric Wilcoxon test were used
to look at differences between the two groups of patients.
Cross-tabulated data were analysed by chi-squared test, or
by Fisher test when the expected cell count was <5. Sur-
vival curves were drawn using the Kaplan–Meier estimate
and compared using the log-rank test.
Results
Diagnosis of FSGS was made at a median of 113 months
(71.5–201.7) before transplantation. FSGS patients had
been on dialysis for 40.9 months (20.2–55.9) before trans-
plantation. No significant difference was seen in the main
demographic characteristics between FSGS patients and
controls. (Table 1).
Patient and graft survival
The actuarial 10- and 15-year patient survival were both
100 % in FSGS patients and 95.5% and 88.3% respec-
tively in controls (P = NS) (Fig. 1). In the control group,
six patients died, two from sepsis, the other four from
cardiac infarct, cerebral thrombosis, non-Hodgkin lym-
phoma, and cancer respectively. In all these patients,
death occurred while their grafts were still functioning
with the last serum creatinine ranging between 0.7 and
3.5 mg/dl.
The actuarial 10- and 15-year graft survival were 60%
and 56% in FSGS patients, and 81% and 64% in the con-
trol group (P = NS) (Fig. 2). In FSGS patients, 17 grafts
were lost (32%), because of recurrence of FSGS in seven
patients, chronic rejection in six, primary nonfunction in
one patient, acute arterial graft thrombosis in one patient,
nonadherence to therapy in one patient, and unspecific
Table 1. Demographic characteristics
of renal transplant recipients with FSGS
and controls.
FSGS Controls P-value
Age (years) at transplant (mean ± SD) 34.1 ± 11.7 34.3 ± 11.6 NS
Gender (male/female) 31/21 62/42 NS
Living/deceased donors 9/43 18/86 NS
Length of dialysis, months
Median (25,75 percentile)
40.9 (20.2–55.9) 39.1 (16.1–55.2) NS
CAPD/HD/pre-emptive transplant 2/49/1 18/84/2 NS
HCV positive/negative 6/46 10/94 NS
Follow-up post-transplant
Median (25,75 percentile)
93.4 (52.2–163.1) 109.4 (55.4–173.2) NS
Nadir serum creatinine (mg/dl) 1.49 ± 0.63 1.37 ± 0.67 NS
FSGS, focal segmental glomerulosclerosis; CAPD, continuous ambulatory peritoneal dialysis; HD,
hemodialysis.
Figure 1 Kaplan–Meier estimates of
patient survival in renal transplanted
patients with focal segmental glomeru-
losclerosis (dashed line)and in controls
(solid line). The numbers below the
graphs are numbers of patients at risk
at basal, at 5, 10, 15 and 20 years.
Renal transplantation of focal segmental glomerularsclerosis Moroni et al.
ª 2009 The Authors
210 Journal compilation ª 2009 European Society for Organ Transplantation 23 (2010) 208–216
chronic lesions in one patient. Twenty-six graft failures
occurred in the control group (25%). Causes of graft
failure were chronic rejection in eight patients, unspecific
sclerosing lesions in seven, primary nonfunctioning kid-
ney in four, recurrence of primary glomerular disease in
four, acute vascular rejection in one, acute arterial graft
thrombosis in one, and irreversible acute cellular rejection
in one. The actuarial 10- and 15-year graft survival cen-
sored by death was not significantly different between the
two groups (P = NS, data not shown)
Post-transplant complications
The number of delayed graft functions, of acute and
chronic rejections, the number of unspecific chronic
lesions and of severe infections were not significantly dif-
ferent between FSGS patients and controls.
In addition to the 13 controls who received a graft
biopsy early after transplant resulting from acute rejection
(reported in Table 2), 30 other controls were submitted
to graft biopsy during a median follow-up of 63.4 months
(36,93) after renal transplant resulting from proteinuria
in 15 cases (associated with an increase in serum creati-
nine in 10) and to a worsening of renal function alone in
the other 15. In seven out of these 30 biopsies (23%)
FSGS was observed. In these cases, focal glomerulosclero-
sis was the accompanying feature of: calcineurin-inhibitor
toxicity in two (proteinuria 0.08 and 0.8 g/24 h), chronic
rejection in two (proteinuria 0.4 and 1.8 g/24 h), unspe-
cific chronic lesions in one (proteinuria 0.12 g/24 h),
transplant glomerulopathy in one (proteinuria 7.6 g/day),
and recurrence of membranoproliferative glomerulone-
phritis in the last case (proteinuria 7 g/day). In another
patient, who developed proteinuria (2 g/24 h) after a shift
from tacrolimus to sirolimus because of a parathyroid
cancer, graft biopsy was not performed. Altogether 16
controls out of 104 (15.4%) developed proteinuria during
the follow-up.
One of the 11 patients with nonbiopsied glomerulone-
phritis developed proteinuria (4 g/day) associated with
rapidly progressive renal insufficiency 142 months after
renal transplant. Graft biopsy showed a crescentic glomer-
ulonephritis. None of the other 10 controls with a non-
biopsied glomerulonephritis developed proteinuria during
a median follow-up of 77.7 months.
Considering FSGS grafts still functioning at the end of
the follow-up (35 out of 52), the mean levels of serum
creatinine and daily proteinuria were respectively
1.57 ± 0.96 mg/dl and 0.27 ± 0.34 g/24 h, not different
from those of controls with functioning grafts (78 out of
104), i.e. serum creatinine 1.53 ± 0.5 mg/dl, and protein-
uria 0.46 ± 0.54 g/day (P: NS).
Outcome of transplant patients with recurrence of FSGS
In 12 out of 52 grafts (23%) of the present series, a
biopsy-proven recurrence of FSGS was diagnosed in com-
parison to 46% recurrences (12 out of 25 grafts) observed
in our Unit between 1969 and 1988 (P = 0.05) (Table 3).
Three out of 12 recurrent grafts were living related
grafts. Nephrotic proteinuria developed within 1–9 days
after renal transplant in nine cases, around 4 weeks in
two cases, and after 11 months in the last one. Renal
%
80.0
100.0 89%
40.0
60.0 84%
20.0
0.0
0.0 P = ns
FSGS 52 37
80%
64%
60%
36%
5.0 10.0 15.0 20.0
years
16 10 3
Controls 104 75 46 25 3
controls pts with FSGS
Figure 2 Kaplan–Meier estimates of
renal survival probability censored for
death in renal transplanted patients with
focal segmental glomerulosclerosis
(dashed line) and in controls (solid line).
The numbers below the graphs are
numbers of patients at risk at basal, at
5, 10, 15 and 20 years.
Table 2. Main complications after kidney transplantation.
FSGS
52 grafts
Controls
104 grafts
P-value
Delayed graft function ‡ 3 days 0 8 NS
Acute rejections 23 (44) 39 (37.5) NS
Vascular rejections 7 4
Cellular rejections 5 9
Clinical acute rejections 11 26
Chronic rejection 6 (11.5) 11 (10.5) NS
Unspecific sclerosing lesions 6 (11.5) 15 (14.4) NS
Arterial hypertension, 49 (94) 98 (94) NS
No. patients with severe infections 26 (46) 40 (38.5) NS
Values in parentheses are percentages.
FSGS, focal segmental glomerulosclerosis.
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biopsy was performed in median 9.5 days (range
2–75 days) after the onset of proteinuria. Segmental
glomerulosclerosis on light microscopy was found in eight
biopsies while in the other four cases glomeruli had
normal appearance at light microscopy but diffuse efface-
ment of epithelial foot processes on electron microscopy.
These 12 recurrences of FSGS occurred in 11 patients
(patient number 8, received two grafts during this study
period). Of them, six received a first renal transplant, one
received a first and a second graft and four a second
graft. One out of the seven first grafts (number 2)
achieved full remission of proteinuria under ACE inhibi-
tors. Fifteen years after renal transplantation mild impair-
ment of graft function occurred followed by the
development of proteinuria of around 1 g/day. A follow-
up graft biopsy was performed that showed chronic rejec-
tion. The graft is still functioning after a mean follow-up
of 240 months. Recurrence led to graft failure in the
other six cases: in number 8 and 10, the graft ceased to
function within 1 month after transplant, another graft
(number 4) was lost 6 months after transplant in spite of
PLX and ACE inhibitors. The last three grafts (number 1,
3, 9), all treated with ACE inhibitors associated with
MPP in one and with PLX in another, achieved partial
and transient remission of nephrotic syndrome and lost
the function respectively 45, 93 and 99 months after
transplantation. Patient 1, and patient 9 received a fol-
low-up graft biopsy 56 months and 22 months respec-
tively after the first biopsy. In patient 1, the second graft
biopsy performed with a serum creatinine of 2 mg/dl and
a proteinuria of 3 g/24 h, showed the progression of
glomerulosclerosis and of tubulointerstitial lesions. In
patient 9, whose basal graft biopsy showed effacement of
epithelial foot processes only, the follow-up biopsy dem-
onstrated a full-blown picture of FSGS (serum creatinine
3.7 mg/dl, proteinuria 8.22 g/24 h).
Three out of these six patients who lost the first graft
because of recurrence of FSGS were re-transplanted. In
one (number 8), FSGS recurred again but proteinuria
remitted with PLX and ACE inhibitors. Fifty-nine months
after the second transplant, the patient has normal renal
function and no proteinuria. The other two grafts are still
functioning 27 and 79 months respectively after the sec-
ond transplant with no signs of recurrence of FSGS. At
the last observation, serum creatinine was 1.4 and.1.9 mg/
dl and proteinuria 0.14 and 0.20 g/24 h respectively. In
the last four patients (numbers 5, 6, 7, 11) who received
a second graft after having lost the first from recurrence
before the commencement of this study, (included in the
previous article) [14], the disease recurred again. One
patient (number 5) was treated with PLX, MPP, and
cyclophosphamide, but the graft was lost 10 months after
transplantation. Seven months after the basal graft biopsy,
this patient received a second biopsy that showed pro-
gression of glomerulosclerosis and of tubulointerstitial
lesions. In the other three patients, proteinuria remitted
under treatment with ACE inhibitors and angiotensin
receptor blockers (ARBs) associated with PLX in two
patients. Their grafts are still functioning at 199, 109 and
73 months after transplantation. Patient 7 who, at basal
graft biopsy had a lesion of segmental sclerosis in one out
of the 12 glomeruli was submitted to a second biopsy
32 months later when he was on complete remission
(serum creatinine 1.1 mg/dl, protienuria 0.23 g/24 h).
The second graft biopsy was normal at light and electron
microscopy.
Table 3. Patients with recurrence of focal segmental glomerulosclerosis in renal transplantation.
Patients Donor Gender
Time of
recurrence
Time of
biopsy
(days)
S.creat
mg/dl
U.Prot
g/24 h
Outcome after therapy At last observation
Therapy PLX-months
S.creat
mg/dl
U.Prot
g/24 h
Follow-up
months
S.Creat
mg/dl
U.prot
g/24 h
1 I Living M 3 Days 19 2 4.42 PLX+ACE 40 1.5 1.1 93 ESRD 4.38
2 I Deceased F 35 Days 75 1 6 ACE 0 1.1 0.1 240 1.9 1.66
3 I Living F 2 Days 47 1.6 6.75 ACE 0 2.2 1.8 99 ESRD
4 I Deceased M 2 Days 28 9.5 5.8 PLX+ACE 3 3.1 14 6 ESRD
5 II Deceased M 30 Days 3 2 4.5 MP+ PLX+Cy 3 2.5 2 10 ESRD
6 II Deceased M 2 Days 6 1.1 4.75 PLX+ACE 9 1 1.29 73 2 0.29
7 II Deceased M 11 Months 6 1.46 4.32 PLX+ACE 10 1.1 0 199 1.26 0.04
8 I Living M 4 Days 2 1.6 7.72 MP 0 5.2 24 1 ESRD
8 II Deceased M 9 Days 7 2.2 7.57 PLX+ACE 19 1.1 0.154 59 1 0.02
9 I Deceased M 7 Days 35 1.18 4.5 MP+ ACE 0 1.8 2.8 45 ESRD
10 I Deceased M 1 Day 12 11.2 8.11 MP+ACE 0 11 9 1 ESRD
11 II Deceased M 6 Days 6 1.1 1.6 ACE 0 1.2 0.6 109 1.15 0.27
I, first renal transplant; II, second renal transplant; S. creat, serum creatinine; U. Prot, urinary protein; PLX, plasmapheresis; ACE, ACE inhibitor;
Cy, cyclophosphamide; ESRD, end-stage renal disease; MPP, methylprednisolone pulses; time of biopsy, time of transplant biopsy; number of days
from clinical diagnosis from recurrence to graft biopsy.
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The comparison of time to recurrence and survival
between the first and the second allograft in patients with
recurrent FSGS in the second allograft is reported in
Table 4.
Altogether, in this series, seven out of the 12 grafts
with recurrence of FSGS (58%) were lost, a percentage
similar to the 50% observed in our previous study [14].
However in the previous study, all recurrent grafts were
lost within 28 months, while in this series three out of
seven grafts were still functioning 4–8 years after trans-
plantation. The other five grafts achieved remission of
nephrotic syndrome and are still functioning after a med-
ian follow-up of 106 months (range 59–240 months),
while none of the recurrent grafts still functioning at the
end of our previous study had achieved remission of
nephrotic syndrome.
The percentage of recurrence in patients with first graft
was 15% while in those with second graft was 62.5%
(P = 0.01). Only one of the five second grafts with recur-
rence (20%) was lost because of recurrence. In our previ-
ous study, only one patient received a second allograft
because of the loss of the first resulting from recurrence.
FSGS recurred in this second graft too and the graft was
lost.
Patients who developed a recurrence of FSGS were
more frequently males (P = 0.02), younger at diagnosis
of the original disease (P = 0.03), and younger at renal
transplant (P = 0.05) than patients who did not develop
recurrence. The duration of the original disease in the
native kidney was shorter in patients who developed
FSGS recurrence than in those who did not (Table 5). In
our previous study, no predictors of recurrence were
found although recurrent patients tended to be younger
at the onset of the disease and to have a shorter dura-
tion of FSGS, when compared with those without recur-
rence.
Treatment with PLX led to partial (one patient) or
complete (three patients) remission of nephrotic syn-
drome and the maintenance of graft function in 80% of
patients in comparison to 33% in nontreated patients
(P = NS). PLX was started within 1 week from the onset
of proteinuria in three patients and within 2 weeks in
two other patients and was continued with variable fre-
quency for 3–40 months. Five out of the 10 grafts that
received ACE inhibitors and/or ARB were lost as well as
the other two recurrent grafts not treated with these
drugs. Four out of the five patients treated with PLX plus
ACE inhibitors (80%) went into complete or partial
remission and maintained graft function in comparison
with two out of the seven not treated (28%; P = NS).
Discussion
There is little information about the long-term outcome
of adults with FSGS submitted to renal transplantation.
In this series, the actuarial 15-year patient survival in
patients with FSGS was 100%, confirming the findings of
previous articles that reported excellent patients’ survival,
although with shorter follow-ups [18]. There are not
many studies that have reported data on graft survival in
adults with FSGS. Pardon et al. [16] reported a graft sur-
vival of 73% at 5 years in 33 transplanted adults with
FSGS, but no comparison with a control group was
made. In 27 adults followed for a mean of 70 months.
Choi et al. [15] reported a 10-year graft survival of 41%
in patients who received a graft from donors younger
than 40 years, while none of the grafts from donors older
than 40 years was functioning at 10 years. In this series,
the actuarial 15-year graft survival was 56% in FSGS
patients and 64% in controls. No difference was seen in
the number of acute and chronic rejections and the risk
of developing severe infections between patients with
FSGS and controls. These data underline the fact that
patients affected by FSGS can obtain a good graft survival
even in the long term. A potential drawback of our con-
trol group is the absence of patients with diabetic- or
ischemic nephropathy, diseases that represent some of the
most prevalent causes of renal transplantation in adults in
Table 4. Comparison of time to
recurrence and of survival between
the first and the second allograft in
patients with recurrent FSGS in the
second allograft.
Patients
First renal allograft Second renal allograft
Time of
recurrence (days)
Follow-up
(months) Outcome
Time of
recurrence
Follow-up
(months) Outcome
5 1 4 ESRD 30 Days 10 ESRD
6 1 18 ESRD 2 Days 73 Functioning graft
7 4 28 ESRD 11 Months 199 Functioning graft
11 2 12 ESRD 6 Days 109 Functioning graft
8 4 1 ESRD 9 Days 59 Functioning graft
ESRD, end-stage renal disease.
Patients 5, 6, 7, 11 received their first allograft during the period of our previous study; patient 8
received both allografts during this study period.
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some, though not in our patient population. Indeed, as
we matched our controls for (the) age of FSGS patients,
the age range of uremic patients with diabetic- or ische-
mic nephropathy was not included.
Recurrence of FSGS is a frequent complication in
transplanted children and adults, and can lead to the loss
of graft in about 50% of the patients [11]. In our previ-
ous experience [14], recurrence occurred in 12 out of 25
transplants performed between 1969 and 1988 (46%). In
this series of 52 renal transplants performed 20 years
later, the rate of recurrence was much lower, 23% after a
mean follow-up of 103 months. As in our previous expe-
rience, the recurrences occured extremely early post-trans-
plant, this could highlight the fact that there is likely a
circulating permeability factor responsible for this process
[2]. Of note, five of these 12 patients with recurrence had
previously lost a first graft from recurrence, a condition
considered as the greatest risk factor for recurrence in a
second transplant [19–21]. If we exclude these five
re-transplanted patients, the rate of recurrence on the first
grafts would be only 15%. As we did not exclude any
patients from transplantation on the basis of the presence
of FSGS, it is possible to speculate that the more potent
immunosuppression, (with more than 60% of patients
receiving triple-drug therapy), may have played a role in
reducing the rate of recurrence of FSGS in recent years.
In this context, it is worth noting that a number of pedi-
atric centers reported the possibility of preventing or
reversing proteinuria through the use of high-dose CsA,
either administered by mouth or intravenously [3,22,23].
The larger use in recent years of ACE inhibitors and/or
ARB may have also been a factor in preventing protein-
uria, at least in milder cases [19].
In this series, 58% of patients with recurrence lost their
grafts, a percentage similar to the 50% observed in our
previous study [14]. However in our previous study, recur-
rent grafts were lost within 28 months while in this series,
three out of seven grafts were still functioning 4–8 years
after transplantation. This difference can be accounted for
by the more frequent use of ACE inhibitors, ARB, and/or
PLX in this series. Therapy with PLX has been advocated
for induction of remission of proteinuria in grafts with
recurrence of FSGS with the aim of removing still uniden-
tified circulating factors which may influence glomerular
basement membrane permeability [1,2,24–26]. PLX has
been employed alone or in association with ACE inhibitors
[19] and with intensified immunosuppression such as
cyclophosphamide [22] or high dose cyclosporine
Table 5. Demographic, clinical and laboratory characteristics of patients with FSGS who relapsed and those who did not.
Grafts with
recurrent FSGS: 12
Nonrecurrent
grafts: 40 P-value
Age at diagnosis of FSGS of the recipient (years) mean ± SD 16.3 ± 6.8 24.1 ± 11.5 0.03
Age at tx (years) mean ± SD 28.4 ± 7.8 35.8 ± 12.2 0.05
Age of donors (years) mean ± SD 32.4 ± 13.5 40 ± 17.8 NS
Gender of the recipient (male/female) 10/2 16/24 0.02
Months between diagnosis of FSGS and ESRD (months) Median
(25,75 percentile)
37.5 (30.1–58.4) 56.2 (32.9–113) 0.1
Duration of dialysis (months) 45 (26.2–132.8) 39.2 (17.3–50.3) 0.04
Median (25,75 percentile)
Type of dialysis HD/CAPD/pre-emptive transplant 11/1/0 30/9/1 NS
Follow-up post-tx (months) Median (25,75 percentile) 66 (8.9–101.1) 98.7 (98.7–163.7) 0.003
Deceased/living donors 9/3 34/6 NS
HCV positive (yes/no) 3/9 3/37 NS
Induction with Basiliximab 3 13 NS
Calcineurin inhibitors therapy 12 40 NS
Triple immunosuppression 6 27 NS
Nadir serum creat. mg/dl mean ± SD 1.4 ± 0.47 1.51 ± 0.67 NS
Arterial hypertension 12 37 NS
Acute rejection 3 20 NS
Chronic rejection grafts 1 5 NS
Unspecific sclerosing lesions 1 5 NS
No. patients with infections 4 22 NS
Final Serum creat. mg/dl mean ± SD 1.4 ± 0.37 1.6 ± 1.02 NS
Final Proteinuria g/24 h mean ± SD 0.46 ± 0.68 0.68 ± 1.4 NS
No. lost kidney 7 (58%) 10 (25%) 0.07
FSGS, focal segmental glomerulosclerosis; tx, transplant; ESRD, end-stage renal disease; CAPD, continuous ambulatory peritoneal dialysis; creat,
creatinina; HD, hemodialysis.
Renal transplantation of focal segmental glomerularsclerosis Moroni et al.
ª 2009 The Authors
214 Journal compilation ª 2009 European Society for Organ Transplantation 23 (2010) 208–216
[23,27,28]. A number of investigators concluded that PLX
was ineffective or of transient benefit [1,29,30]. However,
better results were obtained when treatment with PLX was
given early on [31] and/or for prolonged periods [24,32].
In a review of the literature Bosch and Wendler [33] found
that proteinuria could be improved and renal function sta-
bilized in 58% of adults with recurrent FSGS. When PLX
was used in a prophylactic manner immediately prior to
transplantation, this decreased the incidence of recurrence
to 26% in treated patients vs. 54% in controls. In this ser-
ies, the use of PLX and ACE inhibitors led to a complete
or partial remission of nephrotic syndrome and improved
graft survival in 80% of treated patients. Treatment with
PLX was started on all patients within 1 or 2 weeks after
the onset of proteinuria and was continued for a mini-
mum of 3 months and up to 40 months in one patient.
We do not have any direct experience with the use of rit-
uximab which has been recently used in recurrent FSGS
with controversial results [34,35].
In this study, male gender, and younger age, both at
diagnosis of the original disease and at transplant,
emerged as significant risk factors for recurrence of FSGS
in the graft. Young age at the onset of the disease has
been associated with a higher risk of recurrence in chil-
dren [3,9,36,37] but this association has never been docu-
mented in adults. In pediatric studies, a number of
investigators found that the shorter the interval between
the diagnosis of the original disease in the native kidney
and the development of ESRD, the higher the risk of
recurrence [7,19,21,37,38]. We found that the duration of
the original disease from diagnosis to the development of
ESRD was shorter in recurrent than in nonrecurrent
patients, but the difference was not significant. In contrast
to other studies [15,16], we did not find any significant
differences in the age of donors between patients who
developed and those who did not develop recurrences of
FSGS. On the basis of these results which show a low rate
of recurrence and good graft survival in the long term in
transplant patients with FSGS, we do not feel justified in
excluding any patients with FSGS from transplantation.
However, it is our opinion that a course of prophylactic
pre- and post-transplant PLX particularly in young males
with rapid progression to ESRD may be able to prevent
and/or delay the recurrence. In case of recurrence, our
experience [39] and that of others [28] suggest that
administration of ACE inhibitors along with protracted
PLX treatment can induce or maintain the remission.
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